Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France

Authors

Samira Fafi-Kremer, Timothee Bruel, Yoann Madec, Rebecca Grant, Laura Tondeur, Ludivine Grzelak, Isabelle Staropoli, Francois Anna, Philippe Souque, Catherine Mutter, Nicolas Collongues, Alexandre Bolle, Aurelie Velay, Nicolas Lefebvre, Marie Mielcarek, Nicolas Meyer, David Rey, Pierre Charneau, Bruno Hoen, Jerome De Seze, Olivier Schwartz, Arnaud Fontanet

Background

The serologic response of individuals with mild forms of SARS-CoV-2 infection is poorly characterized.

Methods

Hospital staff who had recovered from mild forms of PCR-confirmed SARS-CoV-2 infection were tested for anti-SARS-CoV-2 antibodies using two assays: a rapid immunodiagnostic test (99.4% specificity) and the S-Flow assay (~99% specificity).The neutralizing activity of the sera was tested with a pseudovirus-based assay.

Results

Of 162 hospital staff who participated in the investigation, 160 reported SARS-CoV- 2 infection that had not required hospital admission and were included in these analyses. The median time from symptom onset to blood sample collection was 24 days (IQR: 21-28, range 13-39). The rapid immunodiagnostic test detected antibodies in 153 (95.6%) of the samples and the S-Flow assay in 159 (99.4%), failing to detect antibodies in one sample collected 18 days after symptom onset (the rapid test did not detect antibodies in that patient). Neutralizing antibodies (NAbs) were detected in 79%, 92% and 98% of samples collected 13-20, 21-27 and 28-41 days after symptom onset, respectively (P=0.02).

Conclusion

Antibodies against SARS-CoV-2 were detected in virtually all hospital staff sampled from 13 days after the onset of COVID-19 symptoms. This finding supports the use of serologic testing for the diagnosis of individuals who have recovered from SARS-CoV-2 infection. The neutralizing activity of the antibodies increased overtime. Future studies will help assess the persistence of the humoral response and its associated neutralization capacity in recovered patients.

https://medrxiv.org/cgi/content/short/2020.05.19.20101832.full.pdf

Overview of SARS-COV-2 studies seroprevalence in context of the worldwide  COVID-19 pandemie. You can register a study here: Contribute

serohub@helmholtz-hzi.de
@serohub on Twitter
hzi-braunschweig/serohub on GitHub